Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Zhonghua Zhong Liu Za Zhi ; 40(5): 384-389, 2018 May 23.
Artigo em Chinês | MEDLINE | ID: mdl-29860767

RESUMO

Objective: To investigate the efficacy and drug related adverse reactions of sorafenib and sunitinib as first-line tyrosine-kinase inhibitors (TKIs) for patients with metastatic renal cell carcinoma (mRCC) and analyze the clinical prognostic factor for survival. Methods: The data of 271 patients with metastatic renal cell carcinoma who had complete clinicopathological data were retrospectively analyzed, including 174 cases in sorafenib group and 97 cases in sunitinib group, to access patients' overall survival (OS) and progression-free survival (PFS). Prognostic values of all characteristics were determined by using univariate and multivariate Cox regression models. Results: The objective response rates (ORR) of the sorafenib and sunitinib groups were 14.9% and 19.6%, respectively, and the disease control rates (DCR) were 85.1% and 88.6%, respectively. No significant difference was found between the sorafenib and sunitinib group in ORR (P=0.325) or DCR (P=0.408). The most common grade 3 to 4 adverse events in the sorafenib group were hand-foot syndrome (6.7%), diarrhea (2.3%), and rash (2.3%). The most common grade 3 to 4 adverse events in the sunitinib group were neutropenia (6.2%), hand-foot syndrome (6.2%), and thrombocytopenia (4.6%). During the follow-up, 97 cases death occurred and 81 cases disease progression occurred in sorafenib group. The median PFS was 12 months (95% CI: 9-15 months), and the median OS was 25 months (95% CI: 21-29 months) in sorafenib group. While 74 cases death occurred and 40 cases disease progression occurred in sunitinib group, the median PFS was 12 months (95% CI: 10-12 months) and the median OS was 23 months (95% CI: 20-32 months) in sunitinib group. No significant difference was found between the sorafenib and the sunitinib group in PFS (P=0.771) or OS (P=0.548). Multivariate analysis showed Fuhrman grades (HR=1.358, 95%CI: 1.004-1.835), number of metastatic sites (HR=1.550, 95%CI: 1.143-2.101) and MSKCC risk grade (Intermediate risk group: HR=1.621, 95%CI: 1.117-2.232; Poor risk group: HR=2.890, 95%CI: 1.942-4.298) were independent prognostic factors for PFS. Fuhrman grades (HR=2.135, 95%CI: 1.533-2.974), number of metastatic sites (HR=1.774, 95%CI: 1.279-2.461) and MSKCC risk grade (Intermediate risk group: HR=1.415, 95%CI: 1.002-1.998; Poor risk group: HR=3.161, 95%CI: 2.065-4.838) were independent prognostic factors for OS. Conclusions: The results of this study indicate that sorafenib and sunitinib are both effective as the first-line TKIs for mRCC patients and sorafenib has comparable efficacy to sunitinib. But they have differences in the incidence of adverse effects. Fuhrman grades, number of metastatic sites and MSKCC risk grade are independent prognostic factors for mRCC patients.


Assuntos
Antineoplásicos/uso terapêutico , Carcinoma de Células Renais/tratamento farmacológico , Carcinoma de Células Renais/secundário , Indóis/uso terapêutico , Neoplasias Renais/tratamento farmacológico , Niacinamida/análogos & derivados , Compostos de Fenilureia/uso terapêutico , Pirróis/uso terapêutico , Antineoplásicos/efeitos adversos , Carcinoma de Células Renais/mortalidade , Diarreia/induzido quimicamente , Progressão da Doença , Intervalo Livre de Doença , Síndrome Mão-Pé/etiologia , Humanos , Indóis/efeitos adversos , Neoplasias Renais/mortalidade , Neoplasias Renais/patologia , Análise Multivariada , Neutropenia/induzido quimicamente , Niacinamida/efeitos adversos , Niacinamida/uso terapêutico , Compostos de Fenilureia/efeitos adversos , Prognóstico , Modelos de Riscos Proporcionais , Pirróis/efeitos adversos , Estudos Retrospectivos , Fatores de Risco , Sorafenibe , Sunitinibe , Trombocitopenia/induzido quimicamente , Resultado do Tratamento
2.
Zhongguo Zhong Yao Za Zhi ; 26(8): 553-5, 2001 Aug.
Artigo em Chinês | MEDLINE | ID: mdl-12776371

RESUMO

OBJECTIVE: To study the chemical constituents of oligostilbenes from Vitis davidii. METHOD: Compounds were isolated with polystyrene resin RA, silica gel and C18 column chromatography. The structures were elucidated by means of spectroscopic evidence. RESULT: Seven compounds were obtained and identified as resveratrol, heyneanol A, ampelopsin E, amurensin B, (+)-epsilon-viniferin, vitisin A and amurensin G. CONCLUSION: All the compounds were isolated from this plant for the first time.


Assuntos
Plantas Medicinais/química , Estilbenos/isolamento & purificação , Vitis/química , Benzofuranos/química , Benzofuranos/isolamento & purificação , Fenóis/química , Fenóis/isolamento & purificação , Resveratrol , Estilbenos/química
3.
Zhongguo Zhong Yao Za Zhi ; 25(9): 541-3, 2000 Sep.
Artigo em Chinês | MEDLINE | ID: mdl-12516464

RESUMO

OBJECTIVE: To study the chemical constituents in the twigs and leaves of Ligustrum obtusifolium. METHOD: Seven compounds were isolated from the ethanol extract of the twigs and leaves by polystyrene resin RA and silica gel column chromatography. The structures were identified by spectral analysis. RESULT: Of the seven compounds isolated six were identified as luteolin, luteolin-4'-O-beta-D-glucopyranoside, (+)-pinoresinol, (+)-pinoresinol-4'-O-beta-D-glucopyranoside, (+)-medioresinol and (-)-olivil. CONCLUSION: luteolin, luteolin-4'-O-beta-D-glucopyranoside, (+)-pinoresinol, (+)-medioresionnol and (-)-olivil were isolated from this plant for the first time.


Assuntos
Flavonoides/isolamento & purificação , Furanos , Lignanas/isolamento & purificação , Ligustrum/química , Folhas de Planta/química , Plantas Medicinais/química , Flavonoides/química , Lignanas/química , Luteolina
4.
J Asian Nat Prod Res ; 2(3): 169-75, 2000.
Artigo em Inglês | MEDLINE | ID: mdl-11256690

RESUMO

A new dimeric stilbene, named shegansu B (1) was isolated from the ethanolic extract of the roots of Belamtantida chinensis (L.) DC., along with the known compounds isorhapontigenin, resveratol, p-hydroxybenzoic acid, iridin, tectoridin, tectorigenin and daucosterol. The structures were elucidated by means of spectroscopic evidence including 2D-NMR studies.


Assuntos
Medicamentos de Ervas Chinesas , Magnoliopsida/química , Estilbenos/isolamento & purificação , Cromatografia , Humanos , Antagonistas de Leucotrienos , Espectroscopia de Ressonância Magnética , Estrutura Molecular , Raízes de Plantas/química , Estilbenos/química
5.
Shi Yan Sheng Wu Xue Bao ; 24(4): 307-15, 1991 Dec.
Artigo em Chinês | MEDLINE | ID: mdl-1796715

RESUMO

A Chinese herb, wikstroemia Chamaedaphen (WC) extract, recently has been shown to be a potential tumor promoting agent on uterine cervical carcinoma induced by HSV-2 or MCA in mice. To determine whether the tumor promoting effects of WC extract were mediated through inhibition of gap junctional intercellular communication (GJIC) with relation to cellular growth, experiments were conducted on Chinese hamster V79 cells and rat WB liver cells by utilization of SLDT method for GJIC detection and cell growth curve examination, 3H-TdR incorporation, mitotic index (MI) and Flow Cytometry (FCM) methods. TPA was used for comparative purpose. WC extract inhibited GJIC and stimulated cell growth in a dose (2-200 micrograms/ml) and time (0-72 hr)-dependent manner in both cell lines. Both WC extract and TPA treatments increased V79 cell growth rate. The average cell doubling-time was decreased from 36.5 hr in control V79 cells to 28.2 hr in WC extract (10 micrograms/ml) and 20.9 hr in TPA (50 ng/ml) treatment by the 3rd day. Stimulating effect of both drugs on DNA synthesis of V79 cells was demonstrated. The results of FCM and MI indicated that the cell number of M-phase cells was increased after drug treatment. It is suggested that (1) tumor promoting effect of WC extract might be mediated through inhibition of GJIC: (2) inhibition of GJIC is closely correlated with increased cell growth rate and entry of cell division cycle.


Assuntos
Carcinógenos/toxicidade , Comunicação Celular/efeitos dos fármacos , Medicamentos de Ervas Chinesas/toxicidade , Junções Intercelulares/efeitos dos fármacos , Animais , Carcinógenos/farmacologia , Divisão Celular/efeitos dos fármacos , Linhagem Celular , Cricetinae , DNA/biossíntese , Medicamentos de Ervas Chinesas/farmacologia , Fibroblastos/citologia , Fígado/citologia , Índice Mitótico/efeitos dos fármacos , Ratos , Acetato de Tetradecanoilforbol/farmacologia , Acetato de Tetradecanoilforbol/toxicidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA